12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lantus insulin glargine: Phase III started

Sanofi (Euronext:SAN; NYSE:SNY), Paris, France
Product: Lantus insulin glargine
Business: Endocrine/Metabolic
Molecular target: Insulin receptor (INSR)
Description: Synthetic sustained-release subcutaneous insulin analog
Indication: Treat Type I diabetes
Endpoint: Change from...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >